Post-hoc analysis of Xiaflex/Xiapex for Peyronie's Disease reported - Auxilium
Auxilium Pharmaceuticals and Swedish Orphan Biovitrum AB announced that data were presented from multiple clinical trials evaluating the use of Xiaflex/Xiapex (collagenase clostridium histolyticum or CCH) in adult patients with Peyronie's disease (PD). A post-hoc analysis of the pooled data from the IMPRESS I and II Phase III trials showed improved clinical outcomes following CCH-treatment regardless of subjects' baseline PD treatment history, erectile function scores, and/or prostatectomy history. The global safety analysis of seven clinical trials of CCH for the treatment of PD shows that the adverse events were mostly localized to the penis, non-serious and resolved without intervention before the next injection.
Serious adverse events (SAEs) related to treatment were also all localized to the penis in these clinical studies. A total of 60 (5.7%) of CCH-treated subjects experienced at least one treatment-emergent SAE, nine of whom experienced treatment-related SAEs (five penile hematoma and four corporal rupture). The data were presented at the 29th Annual European Association of Urology (EAU) Congress.
Related news and insights
Medtronic announced the United States launch of the Penditure left atrial appendage (LAA) exclusion system, an implantable clip preloaded on a single-use delivery system for LAA management during concomitant cardiac surgery procedures
GSK plc announced positive headline results from a planned interim efficacy analysis of the DREAMM-7 head-to-head phase III trial evaluating belantamab mafodotin as a second-line treatment for relapsed or refractory multiple myeloma